In the Androgel litigation, Faruqi & Faruqi, LLP represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott’s branded testosterone drug, AndroGel. The case alleges that Abbott’s predecessor filed baseless patent litigation and entered a series of horizontal market allocation agreements with generic manufacturers Watson and Par/Paddock (also defendants in the case) to delay generic competition in violation of §§ 1 and 2 of the Sherman Act. The class asserts that, as a result of the delay in generic competition, direct purchasers were overcharged by hundreds of millions of dollars.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 02/03/2009
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771